Ligand Historical Income Statement
| LGND Stock | USD 73.90 1.58 2.18% |
Historical analysis of Ligand Pharmaceuticals income statement accounts such as Gross Profit of 87.3 M can show how well Ligand Pharmaceuticals Incorporated performed in making a profits. Evaluating Ligand Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Ligand Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Ligand Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Ligand Pharmaceuticals is a good buy for the upcoming year.
Ligand |
About Ligand Income Statement Analysis
Ligand Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Ligand Pharmaceuticals shareholders. The income statement also shows Ligand investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Ligand Pharmaceuticals Income Statement Chart
Ligand Pharmaceuticals Incorporated Income Statement is one of the three primary financial statements used for reporting Ligand's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ligand Pharmaceuticals revenue and expense. Ligand Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Ligand Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 16.4 M, whereas Total Revenue is forecasted to decline to about 101.8 M. Add Fundamental
Total Revenue
Total revenue comprises all receipts Ligand Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Ligand Pharmaceuticals. It is also known as Ligand Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Cost Of Revenue
Cost of Revenue is found on Ligand Pharmaceuticals income statement and represents the costs associated with goods and services Ligand Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Ligand Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Ligand Pharmaceuticals Incorporated operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most accounts from Ligand Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Ligand Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. At present, Ligand Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 16.4 M, whereas Total Revenue is forecasted to decline to about 101.8 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 136.1M | 140.4M | 109.9M | 98.8M | Cost Of Revenue | 62.2M | 52.8M | 11.6M | 18.5M |
Ligand Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
Ligand Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ligand Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | (798.8M) | 23.4M | 38.3M | 34.2M | 35.6M | 37.4M | |
| Interest Expense | 35.7M | 27.4M | 18.7M | 1.8M | 656K | 623.2K | |
| Total Revenue | 120.3M | 186.4M | 277.1M | 196.2M | 131.3M | 101.8M | |
| Gross Profit | 108.9M | 156M | 215.0M | 143.4M | 119.8M | 87.3M | |
| Other Operating Expenses | 126.0M | 177.7M | 198.2M | 193.2M | 121.5M | 112.8M | |
| Operating Income | (5.7M) | 8.6M | 78.9M | (25.5M) | 9.8M | 10.3M | |
| Ebit | (5.7M) | 8.6M | 78.9M | (25.5M) | 15.6M | 16.4M | |
| Ebitda | (804.5M) | 32.0M | 117.2M | 8.7M | 51.2M | 53.8M | |
| Cost Of Revenue | 11.3M | 30.4M | 62.2M | 52.8M | 11.6M | 18.5M | |
| Total Operating Expenses | 114.7M | 147.3M | 136.1M | 140.4M | 109.9M | 98.8M | |
| Income Before Tax | 796.6M | (10.5M) | 47.3M | 36.0M | 63.7M | 66.8M | |
| Total Other Income Expense Net | 802.4M | (19.1M) | (31.6M) | 61.5M | 53.8M | 56.5M | |
| Net Income | 629.3M | (3.0M) | 57.1M | (5.2M) | 52.2M | 54.8M | |
| Income Tax Expense | 167.3M | (7.6M) | (10.3M) | 41.2M | 9.8M | 6.5M | |
| Research Development | 55.9M | 59.4M | 69.0M | 36.1M | 24.5M | 33.6M | |
| Selling General Administrative | 41.9M | 64.4M | 57.5M | 70.1M | 52.8M | 49.7M | |
| Net Income From Continuing Ops | 629.3M | (3.0M) | 57.6M | (5.2M) | 21.1M | 20.0M | |
| Non Operating Income Net Other | 57.9M | 25.3M | (9.0M) | (12.0M) | (13.8M) | (13.1M) | |
| Net Income Applicable To Common Shares | 629.3M | (3.0M) | 57.6M | (33.4M) | (38.4M) | (36.4M) | |
| Tax Provision | 167.3M | (7.6M) | (10.3M) | 41.2M | 49.6M | 52.1M | |
| Interest Income | 28.4M | 8.1M | 886K | 2.0M | 7.0M | 11.2M | |
| Net Interest Income | (7.3M) | (19.3M) | (18.7M) | 247K | 6.3M | 6.6M | |
| Reconciled Depreciation | 43.7M | 28.0M | 47.2M | 34.2M | 37.9M | 34.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Ligand Pharmaceuticals Incorporated. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Ligand Stock analysis
When running Ligand Pharmaceuticals' price analysis, check to measure Ligand Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ligand Pharmaceuticals is operating at the current time. Most of Ligand Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ligand Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ligand Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ligand Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Ligand Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ligand Pharmaceuticals. If investors know Ligand will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ligand Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.97) | Earnings Share 3.03 | Revenue Per Share 7.591 | Quarterly Revenue Growth (0.44) | Return On Assets 0.0079 |
The market value of Ligand Pharmaceuticals is measured differently than its book value, which is the value of Ligand that is recorded on the company's balance sheet. Investors also form their own opinion of Ligand Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ligand Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ligand Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ligand Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ligand Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ligand Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ligand Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.